Lisa Swanson, MD, FAAD

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

Panelists discuss the unique challenges of managing atopic dermatitis in children compared with adults, focusing on factors such as skin barrier differences, treatment adherence, and the impact on growth and development.

Panelists discuss the mental and physical burden of atopic dermatitis on pediatric patients and their caregivers and share approaches to addressing the psychosocial impact of the condition, highlighting how these factors influence treatment selection and care strategies.

Panelists discuss how atopic dermatitis is linked to other type 2 inflammatory conditions in the pediatric population, exploring the shared immune pathways and comorbidities that connect these disorders.

Panelists discuss the pathophysiology of atopic dermatitis, highlighting the role of type 2 inflammation in driving the disease process and explaining how this inflammation contributes to the characteristic itch-scratch cycle seen in affected individuals.

Swanson shared strategies for treating rural dermatology patients at MOPD 2025, emphasizing effective initial care, the role of telehealth, and practical treatments.

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.

Lisa Swanson, MD, discusses how telemedicine and digital health tools can aid in the management and follow-up care of pediatric patients with vitiligo by enabling remote monitoring, improving access to specialists, and facilitating patient engagement, while emerging research into vitiligo treatments may focus on developing therapies to halt or slow the progression of this autoimmune skin condition.

The panelist discusses advances in targeted therapies, including novel biologics and small molecules, as well as the development of personalized treatment approaches tailored to individual patient characteristics, which hold great promise for improving outcomes and enhancing the quality of life for children living with vitiligo in the future.

Lisa Swanson, MD, discusses providing educational resources and materials that explain vitiligo, dispel myths, and promote understanding.

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gaps in atopic dermatitis management for various patient subgroups.

Swanson shared practical tips from her Elevate-Derm West sessions, empowering clinicians with new strategies for pediatric skin care.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.

Dermatology experts evaluate topical ruxolitinib cream's effectiveness in rapidly relieving itch and offer guidance on its black box warning. They also discuss its efficacy in children under 2, highlighting its suitability for those with tactile sensitivity.

Dr James Del Rosso underscores the importance of phase 2 and dose-ranging studies to uncover efficacy differences between therapies, while the panel explores how clinical data from ruxolitinib trials mirrors real-world outcomes.

James Del Rosso, DO, Brad Glick, DO, MPH, FAAD, and Lisa Swanson, MD, FAAD, address the demand for non-steroidal treatment alternatives while navigating the individualization of data interpretation regarding these treatments.

Swanson shared updates and a look ahead at what is in store for pediatric dermatology.

Drs Lisa Swanson and Robert J. Casquejo express their optimism for the future of plaque psoriasis management, sharing their vision for expanded treatment approvals in the pediatric population affected by this condition.

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Lisa Swanson, MD, FAAD and Robert J. Casquejo, PA-C discuss the shifting treatment landscape, shedding light on phosphodiesterase inhibitors-4 (PDE4) and comment on why it holds promise as a therapeutic target for immune-mediated diseases.

Drs Lisa Swanson and Robert J. Casquejo elaborate on their treatment selection approach for plaque psoriasis, underscoring the significance of systemic treatments and their proven efficacy in managing this condition.

Experts in dermatology share insights on considering the location's impact in treating plaque psoriasis, focusing on challenges with scalp involvement and addressing limitations with topical therapies.

Lisa Swanson, MD, FAAD and Robert J. Casquejo, PA-C highlight the impact of plaque psoriasis on both moderate and mild patients, emphasizing the importance of addressing these concerns in patient care.

Lisa Swanson, MD, PhD, delves into clinical pearls from her SDPA fall conference sessions on infantile hemangiomas and challenging cases in pediatric dermatology.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.